Lannett Files Abbreviated New Drug Applications

In a significant move to further augment its product pipeline, Lannett has filed with the FDA two abbreviated new drug applications (ANDAs).

These drug applications bring to 11 the number of ANDAs the company currently has pending at FDA. The company also said that it has in-licensed four additional product candidates. Two ANDAs have been licensed and site change applications are expected to be filed with the FDA by the beginning of the second quarter.

Additionally, two product formulas have been licensed, and for these products ANDAs will be filed.